ACHV vs IKT
ACHV: A clinical-stage biotech developing cytisinicline for smoking cessation and nicotine dependence, preparing for commercialization after completing key clinical trials. IKT: A pre-revenue biotech company developing IKT-001, a novel therapeutic targeting pulmonary arterial hypertension, currently in Phase 3 clinical trials with no approved products or operating revenue.
Side-by-side fundamentals
| Metric | ACHV | IKT | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $6.31 | $2.17 | |
| Market cap as of 2026-07-23 | $646M | $287M | |
| Net margin as of 2026-07-23 | -94.7% | -5981.3% | ACHV higher |
| Gross margin as of 2026-07-23 | -98.8% | n/a | |
| Operating margin as of 2026-07-23 | -106.5% | -6253.1% | ACHV higher |
| ROE as of 2026-07-23 | -193.5% | -57.1% | IKT higher |
| ROA as of 2026-07-23 | -111.9% | -52.8% | IKT higher |
| Debt / equity as of 2026-07-23 | 1.40 | 0.00 | IKT lower |
| Revenue growth (YoY) as of 2026-07-23 | -89.3% | n/a | |
| Beta as of 2026-07-23 | 2.28 | 0.97 | |
| 1-year return as of 2026-07-22 close | +144.4% | +18.6% | ACHV higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.